October 26, 2022 Press release - Regulatory Invitation to Targovax’s third quarter 2022 presentation, Thursday 3 November
August 18, 2022 Press release - Regulatory Targovax ASA: Second quarter and first half year 2022 results
June 7, 2022 Press release - Regulatory Targovax ASA: Registration of share capital increase following settlement of restricted stock units and exercise of employee options
May 31, 2022 Press release - Regulatory Targovax ASA: Mandatory notification of trade by primary insiders pertaining to RSUs
May 31, 2022 Press release - Regulatory Targovax ASA: Exercise of options, settlement of restricted stock units and resolutions to increase the share capital
May 11, 2022 Press release - Regulatory Targovax announces clinical collaboration with Agenus for upcoming ONCOS-102 phase 2 melanoma trial
April 20, 2022 Press release - Regulatory Targovax ASA: Issuance of restricted stock units (RSUs) to the board members
March 8, 2022 Press release - Regulatory Targovax ASA: Registration of share capital increases following exercise of options
March 2, 2022 Press release - Regulatory Targovax ASA: Mandatory notification of trade by primary insider in connection with settlement of RSUs
March 2, 2022 Press release - Regulatory Targovax ASA: Exercise of options under LTI program, settlement of RSUs and resolution to increase the share capital
February 28, 2022 Press release - Regulatory Targovax ASA strengthens management with Lubor Gaal as Chief Financial Officer
February 9, 2022 Press release - Regulatory Targovax ASA: Invitation to presentation of Targovax’s fourth quarter 2021 results, Thursday 17 February
February 1, 2022 Press release - Regulatory Targovax and Prof. Michael Uhlin at Karolinska Institutet enter research collaboration
January 12, 2022 Press release - Regulatory Targovax ASA: Targovax awarded NOK 8.2m grant by Innovation Norway
